XenoPort, Dr. Reddy’s Laboratories Ltd. deal

XenoPort granted Dr. Reddy’s exclusive, U.S. rights to develop and commercialize XP23829. XenoPort will receive $47.5 million up front and is eligible for up to $190 million in regulatory milestones and $250 million in commercial milestones, plus royalties up to the mid-teens. XenoPort also will receive $2.5 million upon the transfer of clinical trial materials to Dr. Reddy’s. ...